THE CIRCUMCISION REFERENCE LIBRARY


JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Volume 40, Number 3: Pages 451-7,
March 1999.



Penile lichen sclerosus et atrophicus treated with
clobetasol dipropionate 0.05% cream:
a retrospective clinical and histopathological study.

Dahlman-Ghozlan K, Hedblad MA, von Krogh G.

Department of Dermatovenereology,
Karolinska Hospital,
Stockholm, Sweden.

BACKGROUND: Treatment with clobetasol propionate 0.05% cream is effective against lichen sclerosus et atrophicus (LSA) of the vulva.

OBJECTIVE: The purpose of this study was to retrospectively evaluate whether clinical and histologic responses to topical clobetasol can be accomplished in penile LSA.

METHODS: A self-assessment questionnaire was obtained from 22 men with LSA, and a clinical examination was performed in 21 of them. Biopsy specimens from 15 cases were compared before and after treatment.

RESULTS: Itching, burning, pain, dyspareunia, phimosis, and dysuria decreased significantly (P < .001 to .05) after 1 to 2 daily applications, for a mean of 7.1 weeks (2-16 weeks). Additional operation for phimosis was required in 6 of the 22 men. All histologic LSA criteria were significantly (P < .01 to .05) reduced after treatment.

CONCLUSION: Topical treatment of penile LSA with clobetasol propionate represents a safe and effective therapy with no risk of epidermal atrophy but with some potential for triggering latent infections, most importantly human papillomavirus.


Citation:
(File revised 7 April 2008)

http://www.cirp.org/library/treatment/BXO/dahlman-ghozlan1/